August 21, 2018
Dana-Farber Researcher Sees Biomarker Potential in ESR1 Mutations BookmarkEmma Shtivelman, PhD
Excerpt from OncLive:
“As a medical oncologist and investigator, Rinath M. Jeselsohn, MD, focuses on the detection and clinical implications of ESR1 mutations in estrogen receptor–positive breast cancer. She is a member of the research team in the lab of Myles A. Brown, MD, at Dana-Farber Cancer Institute in Boston, Massachusetts, where investigators are seeking to elucidate the factors underlying the mechanisms of hormone responsiveness, particularly steroid hormone receptors, in human cancers.
“Jeselsohn, who has led numerous studies into ESR1 mutations, discussed the field in an interview with OncologyLive®.”
Go to full article published by OncLive on Aug 3, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
October 30, 2015
To Type or to Print? Oncotype DX and Mamma/BluePrint Tests for Breast CancerEmma Shtivelman, PhD
Women diagnosed with localized breast cancer face difficult decisions with their doctors. What kind of neoadjuvant (before surgery) treatment to choose? Should chemotherapy follow surgery? Based on the subtype of breast cancer, should specific chemotherapy drugs be used?
June 16, 2015
ASCO Highlight: Another Treatment Option for ER-Positive Breast CancerEmma Shtivelman, PhD
Earlier this year, a new treatment option was added to the arsenal for ER-positive breast cancer in postmenopausal women when the U.S. Food and Drug Administration (FDA) approved the combination of letrozole (Femara) and palbociclib (Ibrance).